Literature DB >> 8882377

Causes and treatment of bone pain of malignant origin.

B Thürlimann1, N D de Stoutz.   

Abstract

Pain relief has been one of the oldest and most important duties of the physician. There has been little change with regard to this obligation of all caregivers. One-third of patients with advanced cancer will develop clinically relevant skeletal metastases and chronic pain during the course of their disease. All physicians involved in the treatment of cancer patients should know the basic principles of pain treatment. These are described in the following article with special regard to bone pain of malignant origin. Correct assessment of pain intensity and frequency, as well as of the probable causes of pain, and the administration of adequate analgesic treatment should achieve satisfactory results in the vast majority of patients. Every physician should obtain detailed knowledge of the indications and adequate administration of pain-killing therapy as well as possible adverse effects and their successful treatment. It is important in particular to concentrate on a few nonsteroidal anti-inflammatory drugs (NSAIDs) as well as opiates. Knowledge of adequate doses, maximal recommended daily doses, pharmacological properties, important adverse effects and interactions is essential for success in the daily routine. Only by selecting 2 or 3 drugs from each step in the analgesic ladder (WHO) will the nonspecialised physician obtain sufficient experience for optimal analgesia. Physicians should also not hesitate to contact other specialists (medical oncologists, radiotherapists, neurosurgeons, anaesthesiologists and others) in order to maximise benefit for an individual patient.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882377     DOI: 10.2165/00003495-199651030-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  49 in total

1.  Morphine intoxication during acute reversible renal insufficiency.

Authors:  R L Fainsinger; M J Miller; E Bruera
Journal:  J Palliat Care       Date:  1992       Impact factor: 2.250

Review 2.  Cancer pain relief and palliative care. Report of a WHO Expert Committee.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1990

3.  Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer.

Authors:  E Bruera; C Brenneis; A H Paterson; R N MacDonald
Journal:  J Pain Symptom Manage       Date:  1989-03       Impact factor: 3.612

4.  Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.

Authors:  L A García Rodríguez; H Jick
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

5.  Breakthrough pain: definition, prevalence and characteristics.

Authors:  Russell K Portenoy; Neil A Hagen
Journal:  Pain       Date:  1990-06       Impact factor: 6.961

6.  Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.

Authors:  R Lahtinen; M Laakso; I Palva; P Virkkunen; I Elomaa
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

7.  A double-blind, crossover trial of intravenous clodronate in metastatic bone pain.

Authors:  D S Ernst; R N MacDonald; A H Paterson; J Jensen; P Brasher; E Bruera
Journal:  J Pain Symptom Manage       Date:  1992-01       Impact factor: 3.612

8.  Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons.

Authors:  M R Griffin; J M Piper; J R Daugherty; M Snowden; W A Ray
Journal:  Ann Intern Med       Date:  1991-02-15       Impact factor: 25.391

9.  Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

Authors:  A H Paterson; T J Powles; J A Kanis; E McCloskey; J Hanson; S Ashley
Journal:  J Clin Oncol       Date:  1993-01       Impact factor: 44.544

10.  Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells.

Authors:  M Haq; D Goltzman; G Tremblay; P Brodt
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

View more
  5 in total

Review 1.  A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain.

Authors:  Bao Yanju; Liping Yang; Baojin Hua; Wei Hou; Zhan Shi; Weidong Li; Conghuang Li; Cihui Chen; Rui Liu; Yinggang Qin; Wenliang Lv
Journal:  Support Care Cancer       Date:  2013-11-26       Impact factor: 3.603

2.  Relief of pain from osseous metastatic lesions.

Authors:  R P Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

3.  Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKCε pathway in dorsal root ganglion neurons.

Authors:  Hai-Li Pan; Yu-Qiu Zhang; Zhi-Qi Zhao
Journal:  Mol Pain       Date:  2010-12-01       Impact factor: 3.395

4.  Comparison of single versus multiple fractions for palliative treatment of painful bone metastasis: first study from north west India.

Authors:  Akhil Kapoor; Mukesh Kumar Singhal; Puneet Kumar Bagri; Raj Kumar Nirban; Sitaram Maharia; Satya Narayan; Harvindra Singh Kumar
Journal:  Indian J Palliat Care       Date:  2015 Jan-Apr

5.  Effectiveness of advanced nursing care (ANC) on bone cancer pain, psychological disorders and quality of life in patients with primary bone cancers: A protocol for a PRISMA-compliant meta-analysis.

Authors:  Lekun Li; Yujie Liu; Xiaofeng Ren; Kai Qu; Xiaona Liu
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.